Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects
LA Dalvin, CL Shields, M Orloff, T Sato, JA Shields - Retina, 2018 - journals.lww.com
Purpose: To review immune checkpoint inhibitor indications and ophthalmic side effects.
Methods: A literature review was performed using a PubMed search for publications …
Methods: A literature review was performed using a PubMed search for publications …
Modern treatment of retinoblastoma: A 2020 review
D Ancona-Lezama, LA Dalvin… - Indian journal of …, 2020 - journals.lww.com
Retinoblastoma management remains complex, requiring individualized treatment based on
International Classification of Retinoblastoma (ICRB) staging, germline mutation status …
International Classification of Retinoblastoma (ICRB) staging, germline mutation status …
Glaucoma secondary to intraocular tumors: mechanisms and management
DA Camp, P Yadav, LA Dalvin… - Current opinion in …, 2019 - journals.lww.com
Intraocular tumors can produce secondary glaucoma. Treatment of the primary tumor can
sometimes resolve the glaucoma. Topical, oral, or laser therapies can be considered …
sometimes resolve the glaucoma. Topical, oral, or laser therapies can be considered …
Choroidal nevus imaging features in 3,806 cases and risk factors for transformation into melanoma in 2,355 cases: the 2020 Taylor R. Smith and Victor T. Curtin …
Purpose: To use multimodal imaging for identification of risk factors for choroidal nevus
transformation into melanoma. Methods: Retrospective chart review of 3806 consecutive …
transformation into melanoma. Methods: Retrospective chart review of 3806 consecutive …
[HTML][HTML] International electronic health record-derived post-acute sequelae profiles of COVID-19 patients
HG Zhang, A Dagliati, Z Shakeri Hossein Abad… - NPJ digital …, 2022 - nature.com
The risk profiles of post-acute sequelae of COVID-19 (PASC) have not been well
characterized in multi-national settings with appropriate controls. We leveraged electronic …
characterized in multi-national settings with appropriate controls. We leveraged electronic …
Parkinson disease and melanoma: confirming and reexamining an association
Objective To examine an association between melanoma and Parkinson disease (PD).
Patients and Methods Phase I: Rochester Epidemiology Project records were used to …
Patients and Methods Phase I: Rochester Epidemiology Project records were used to …
[HTML][HTML] Coats disease in 351 eyes: analysis of features and outcomes over 45 years (by decade) at a single center
CL Shields, S Udyaver, LA Dalvin… - Indian journal of …, 2019 - journals.lww.com
Purpose: To assess features and outcomes of Coats disease over 5-decades. Methods:
Retrospective review of Coats disease patients at a single center. Features and outcomes …
Retrospective review of Coats disease patients at a single center. Features and outcomes …
Genetic analysis of uveal melanoma in 658 patients using the cancer genome atlas classification of uveal melanoma as A, B, C, and D
Purpose The Cancer Genome Atlas (TCGA) classification has been validated for uveal
melanoma (UM) prognostication. We applied TCGA classification to UM biopsied using fine …
melanoma (UM) prognostication. We applied TCGA classification to UM biopsied using fine …
Visual outcome at 4 years following plaque radiotherapy and prophylactic intravitreal bevacizumab (every 4 months for 2 years) for uveal melanoma: comparison with …
CL Shields, LA Dalvin, M Chang… - JAMA …, 2020 - jamanetwork.com
Importance Radiation retinopathy following plaque radiotherapy for uveal melanoma can
lead to vision loss that might be avoided with prophylactic anti–vascular endothelial growth …
lead to vision loss that might be avoided with prophylactic anti–vascular endothelial growth …
Imaging findings of pediatric orbital masses and tumor mimics
AK Joseph, JB Guerin, LJ Eckel, LA Dalvin… - Radiographics, 2022 - pubs.rsna.org
Pediatric orbital masses are not common but encompass a wide spectrum of benign and
malignant entities that range from developmental anomalies to primary and secondary …
malignant entities that range from developmental anomalies to primary and secondary …